

Odense, 14<sup>th</sup> of April 2025

Att.: 25th WHO Expert Committee on Selection and Use of Essential Medicines  
EML Secretariat, [emlsecretariat@who.int](mailto:emlsecretariat@who.int)

**Subject: "A.19 Methylphenidate – attention deficit hyperactivity disorder"**

We hereby confirm that the Danish ADHD-organization supports the addition of methylphenidate-based medication to The WHO Essential Medicines List, as further detailed in: "A.19 Methylphenidate – attention deficit hyperactivity disorder."

ADHD medication based on the active ingrediency methylphenidate have long since been proven to be an effective option regarding treatment of ADHD, for both children and adults alike.

Considering the extensive research already available and researched carried out for many years, we do find that it would be beneficial to include methylphenidate in the WHO Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc).

Best regards

Trish Nymark  
Chairman of Board  
Danish ADHD-organization  
[www.adhd.dk](http://www.adhd.dk)